The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 2 May 2006, www.theannals.com, DOI 10.1345/aph.1G006.
 The Annals of Pharmacotherapy: Vol. 40, No. 5, pp. 939-942. DOI 10.1345/aph.1G006
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McBayne, T. O
Right arrow Articles by Siddall, O. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McBayne, T. O
Right arrow Articles by Siddall, O. M

DRUG INFORMATION ROUNDS

Montelukast Treatment of Urticaria

Tyrone O McBayne, PharmD

Clinical Assistant Professor, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA

O'Rita M Siddall, PharmD

Drug Information Specialist, College of Pharmacy, Xavier University of Louisiana

Reprints: Dr. McBayne, College of Pharmacy, Xavier University of Louisiana, 1 Drexel Dr./Dept Clin/Admin Sciences, New Orleans, LA 70125-1098, fax 504/520-7971, tmcbayne{at}xula.edu

OBJECTIVE: To review clinical trial data to determine the benefits of using montelukast alone or as combination therapy in the treatment of urticaria.

DATA SOURCES: MEDLINE (1966-March 2006) and International Pharmaceutical Abstracts (1970-October 2005) were searched to find clinical trial publications that addressed the use of montelukast in urticaria.

DATA SYNTHESIS: Six clinical trials were identified. Montelukast was compared alone and as combination therapy with nonsedating histamine1-receptor antagonists to determine efficacy and safety. Patients had chronic or physical urticaria. The results were mixed. Some studies demonstrated that montelukast can decrease urticarial symptoms with minimal adverse effects, while others found no differences.

CONCLUSION: Large-scale, controlled trials are needed to determine which patients would likely benefit from treatment with montelukast.

Key Words: montelukast, urticaria

Published Online, May 2, 2006. www.theannals.com, DOI 10.1345/aph.1G006




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.